Covid-fighting Winter Park firm expands arsenal with acquisition

ORLANDO, Fla. — Editor’s note: This story is available as a result of a content partnership between WFTV and the Orlando Business Journal.

A local biopharmaceutical firm’s efforts to develop treatments for diseases, including Covid-19, will get a shot in the arm after it bought another drug business.

Cytocom Inc. purchased Frederick, Maryland-based ImQuest Life Sciences Inc. for an undisclosed amount, Cytocom announced July 20. The deal gives Winter Park-based Cytocom access to ImQuest employees and resources, including labs certified to test coronavirus, Cytocom CEO Michael Handley told OBJ via email.

“These capabilities will provide us with the ability to optimize the dosing of CYTO-201, our lead compound, for human studies.”

Click here to read Alex Soderstrom’s story on the Orlando Business Journal’s website.